Celldex Therapeutics, Inc. (CLDX)
27.53
-1.40
(-4.84%)
USD |
NASDAQ |
Oct 16, 16:00
27.53
0.00 (0.00%)
After-Hours: 18:28
Celldex Therapeutics EPS Diluted (Quarterly) : -0.9443 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.9443 |
| March 31, 2026 | -1.182 |
| December 31, 2025 | -1.223 |
| September 30, 2025 | -1.009 |
| June 30, 2025 | -0.8525 |
| March 31, 2025 | -0.8104 |
| December 31, 2024 | -0.7097 |
| September 30, 2024 | -0.6354 |
| June 30, 2024 | -0.5429 |
| March 31, 2024 | -0.5573 |
| December 31, 2023 | -0.8324 |
| September 30, 2023 | -0.8096 |
| June 30, 2023 | -0.6455 |
| March 31, 2023 | -0.6219 |
| December 31, 2022 | -0.562 |
| September 30, 2022 | -0.5709 |
| June 30, 2022 | -0.77 |
| March 31, 2022 | -0.4932 |
| December 31, 2021 | -0.4315 |
| September 30, 2021 | -0.45 |
| June 30, 2021 | -0.3376 |
| March 31, 2021 | -0.4175 |
| December 31, 2020 | -0.5534 |
| September 30, 2020 | -0.3621 |
| June 30, 2020 | -0.4996 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.7253 |
| December 31, 2019 | -0.6354 |
| September 30, 2019 | -0.7468 |
| June 30, 2019 | -0.8442 |
| March 31, 2019 | -1.402 |
| December 31, 2018 | -0.8086 |
| September 30, 2018 | -0.6637 |
| June 30, 2018 | -1.65 |
| March 31, 2018 | -12.60 |
| December 31, 2017 | -0.45 |
| September 30, 2017 | -3.00 |
| June 30, 2017 | -3.45 |
| March 31, 2017 | -4.20 |
| December 31, 2016 | -4.50 |
| September 30, 2016 | -4.35 |
| June 30, 2016 | -4.80 |
| March 31, 2016 | -5.25 |
| December 31, 2015 | -4.95 |
| September 30, 2015 | -4.80 |
| June 30, 2015 | -4.95 |
| March 31, 2015 | -4.95 |
| December 31, 2014 | -5.40 |
| September 30, 2014 | -4.65 |
| June 30, 2014 | -4.80 |
| March 31, 2014 | -4.95 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Gilead Sciences, Inc. | -8.444 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -73.50M |
| Revenue (Quarterly) | 0.022M |
| Total Expenses (Quarterly) | 73.52M |
| Enterprise Value | 1.565B |
| Gross Profit Margin (Quarterly) | -4.00K% |
| Profit Margin (Quarterly) | -334.1K% |
| Earnings Yield | -15.83% |
| Normalized Earnings Yield | -15.83 |